ConductScience.org, home

Paper · 37204656

An international multidisciplinary consensus statement on MAFLD and the risk of CVD.

Zhou XD and 47 others. Hepatol Int, 2023. Cited by 176 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Papers, record 37204656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37204656

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
PubMed
Journal
Hepatol Int
PubMed
Year
2023
PubMed
Publication types
Journal Article, Consensus Statement
PubMed
Citations, by iCite
176
iCite
Relative citation ratio, by iCite
19.9
iCite
Revised in PubMed
2026-03-04
PubMed

Authors48

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou XDXiao-Dong
2Targher GGiovanni
3Byrne CDChristopher D
4Somers VVirend
5Kim SUSeung Up
6Chahal CAAC Anwar A
7Wong VWVincent Wai-Sun
8Cai JJingjing
9Shapiro MDMichael D
10Eslam MMohammed

1 to 10 of 48Source PubMed

See all 48 authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Diabetes Mellitus, Type 2Major topic
Liver DiseasesMajor topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Humans
Asia

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References150

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126,707,365Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016https://conductscience.org/library/papers/26707365PubMed
228,714,183The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018https://conductscience.org/library/papers/28714183PubMed
332,278,004A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol2020https://conductscience.org/library/papers/32278004PubMed
435,709,820Promoting the term MAFLD: China in action.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35709820PubMed
532,044,314MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.Gastroenterology2020https://conductscience.org/library/papers/32044314PubMed
632,701,591From NAFLD to MAFLD: a "redefining" moment for fatty liver disease.Chin Med J (Engl)2020https://conductscience.org/library/papers/32701591PubMed
733,220,154The NAFLD-MAFLD debate: Eminence vs evidence.Liver Int2021https://conductscience.org/library/papers/33220154PubMed
835,004,952Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future.Hepatobiliary Surg Nutr2021https://conductscience.org/library/papers/35004952PubMed
932,461,575From NAFLD to MAFLD: when pathophysiology succeeds.Nat Rev Gastroenterol Hepatol2020https://conductscience.org/library/papers/32461575PubMed
1036,463,192Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.Cardiovasc Diabetol2022https://conductscience.org/library/papers/36463192PubMed

Cited by112

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 176 citations.

PMIDTitleJournalYearIn PapersSource
42,983,650Association between the red blood cell distribution width to albumin ratio and cardiovascular outcomes in MASLD patients: a national cohort study integrating machine learning.BMC Cardiovasc Disord2026https://conductscience.org/library/papers/42983650PubMed
42,888,835Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality.Med Sci Monit2026https://conductscience.org/library/papers/42888835PubMed
42,857,521Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42857521PubMed
42,781,745The convergent roles of metabolic dysfunction, alcohol, and iron in steatotic liver disease: a review.Biosci Rep2026https://conductscience.org/library/papers/42781745PubMed
42,717,057Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/42717057PubMed
42,668,768Odds for Presence of Metabolic Dysfunction Associated Steatotic Liver Disease ( MASLD) in Individuals with Reported Hepatic Steatosis on Ultrasound.Pak J Med Sci2026https://conductscience.org/library/papers/42668768PubMed
42,668,515The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023.EClinicalMedicine2026https://conductscience.org/library/papers/42668515PubMed
42,590,200Adiposity and Cumulative Cardiometabolic Risk Factors as Determinants of Hepatic Steatosis Severity in Postmenopausal Women.J Clin Med2026https://conductscience.org/library/papers/42590200PubMed
42,514,401ZFP90 Serves as a Transcriptional Brake on NF-κB Signaling to Attenuate Diet-Induced MASLD Progression.Nutrients2026https://conductscience.org/library/papers/42514401PubMed
42,500,251Reframing glucolipid metabolic disorders through the lens of the oral microbiome: from pathophysiological mechanisms to translational potential.Front Nutr2026https://conductscience.org/library/papers/42500251PubMed

1 to 10 of 112

See all 112 cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37204656

GET https://conductscience.org/api/papers/v1/37204656/authors?page=2